enGene Therapeutics Inc.
ENGN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$1.56
KIRA · Stoqly’s AI analyst, in plain words
- enGene Therapeutics Inc. lost $117M in fiscal 2025. From fiscal 2022 to 2025, diluted EPS grew −62.7% a year.
- Free cash flow was −$101M in fiscal 2025, — of revenue.
Market cap
$109M
P/E
0.6x
Revenue
—
Net income
−$117M
Free cash flow
−$101M
Operating margin
—
enGene Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$117M
No. It lost money last year.
How is the share priced?
0.6x
One share costs 0.6 times its yearly profit per share.
What enGene Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- October 31, 2025
- Latest annual report
- 10-K · Dec 22, 2025
- Legal name
- enGene Therapeutics Inc.
- CIK
- 0001980845
enGene Therapeutics Inc. · ENGN
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$24.5M | −$99.9M | −$55.1M | −$117M |
| Diluted EPS | $44.30 | $151.22 | $1.46 | $2.29 |
| Cash | ||||
| Cash from operations | −$17.6M | −$24.7M | −$48.3M | −$99.2M |
| Capital expenditure | $0.2M | $0.3M | $0.9M | $1.5M |
| Free cash flow | −$17.7M | −$25.1M | −$49.2M | −$101M |
| Dividends paid | — | $0.0M | — | — |
| Share count change | — | 5.7% | 5,355.1% | 35.3% |
| Debt and strength | ||||
| Cash and short-term investments | $20.4M | $81.5M | $238M | $194M |
| Shareholders' equity | −$76.6M | $72.5M | $273M | $168M |
| Current ratio | 4.4x | 16.3x | 16.9x | 6.3x |
| Interest coverage | −13.7x | −5.3x | −22.3x | −41.1x |
| Returns and quality | ||||
| Return on equity | — | — | −32.0% | −53.3% |
| Return on tangible equity | — | −144.5% | −20.2% | −69.9% |
| Altman Z'' | −16.0 | 1.8 | 8.3 | −0.9 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
enGene Therapeutics Inc. · ENGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.56 a share, the company is worth $109M: 0.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001980845). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.